Hard to swallow

When NPS Pharmaceuticals received federal approval to sell Gattex earlier this year, it was great news for those who suffer from short-bowel syndrome — a very rare disease.
It also was great news for the Bedminster company, which stands to benefit from $50 million in tax credit for developing this so-called orphan drug.

Read More »